Drugs Channel
Topics & Medications
Quicklinks
Related Channels

Lofibra Precautions and Warnings

An understanding of Lofibra precautions and warnings can help better determine whether it is suitable for you and what potential complications exist. People who should not take Lofibra include those who are allergic to it, those with severe liver or kidney disease, and those with gallbladder disease. Lofibra precautions and warnings extend to an increase in liver enzymes and serious muscle problems, as well as an increased risk of developing gallstones.

Lofibra: What Should I Tell My Healthcare Provider?

Prior to taking Lofibra® (fenofibrate), you should let your healthcare provider know if you have:
 
  • Diabetes
  • Gallbladder disease or gallstones
  • Heart disease
  • Kidney disease or kidney failure
  • Liver disease or liver failure
  • Thyroid gland problems
  • An allergy to Lofibra or to any other medications, foods, dyes, or preservatives.
     
It is also important to let your healthcare provider know if you are:
 
  • Pregnant or planning on becoming pregnant
  • Breastfeeding
  • A frequent user of alcoholic beverages.
     
Tell your healthcare provider about all other medicines you are currently taking, including prescription and non-prescription medicines, vitamins, and herbal supplements.
 

Specific Lofibra Precautions and Warnings

Some precautions and warnings to be aware while taking Lofibra include:
 
  • If you are over the age of 65 or have kidney problems, your healthcare provider may choose to start you at a lower dose than normal.
     
  • Lofibra can interact with certain medications (see Lofibra Drug Interactions).
     
  • Lofibra has been known to cause an increase in liver enzymes. Therefore, it is recommended that you have a blood test that looks at your liver function before starting Lofibra and then again several months after treatment has started. These tests may also be recommended if the Lofibra dosage is changed (see Lofibra and Liver Problems).
     
  • Lofibra can increase the cholesterol content in the bile, leading to gallstones. Your healthcare provider may decide to have you stop taking Lofibra if gallstones are found in your body.
     
  • Lofibra has been associated with the rare but serious condition known as rhabdomyolysis (severe breakdown of muscles). Your risk increases if you are elderly, have kidney disease, or are not being properly treated for hypothyroidism. Let your healthcare provider know immediately if you experience any muscle pain, tenderness, or weakness, especially if they are accompanied by unexplained tiredness or fever (see Lofibra and Muscle Pain).
     
  • Lofibra has been shown to cause a decrease in certain blood cells at the beginning of therapy. Your healthcare provider may decide to monitor your blood counts more closely during the first 12 months of your treatment.
     
  • Lofibra is considered a pregnancy Category C medicine. This means it has not been studied in pregnant women. However, when studied in animals, it did produce a negative effect on the fetus. If you are pregnant, you should only take Lofibra if the benefit outweighs the possible risk to your unborn child. If you become pregnant while taking Lofibra, contact your healthcare provider immediately.
     
  • If you are nursing, it is not known if Lofibra passes through your milk, although it has been shown to increase the risk of tumors in nursing animals. Therefore, if you are nursing and taking Lofibra, it is recommended that you either stop nursing or discontinue Lofibra. This decision should be made by your healthcare provider.
     
Ouch! 6 Types of Pain You Might Experience When Getting a Stent

Lofibra Medication

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.